| 自体CIK细胞联合同步放化疗治疗局部晚期食管癌的临床研究 |
| |
| 引用本文： | 舒 心,李广欣,朱曦龄,黎 功,甘 泉,汪治宇.自体CIK细胞联合同步放化疗治疗局部晚期食管癌的临床研究[J].现代肿瘤医学,2015,0(10):1376-1380. |
| |
| 作者姓名： | 舒 心 李广欣 朱曦龄 黎 功 甘 泉 汪治宇 |
| |
| 作者单位： | 1.武警总医院肿瘤二科，北京 100039；
2.武警北京总队第三医院肿瘤科，北京 100141；
3.武警总医院营养科，北京 100039；
4.河北医科大学第四医院生物治疗科，河北 石家庄 050011 |
| |
| 摘 要： | 目的:探讨自体CIK细胞联合同步放化疗对局部晚期食管癌患者的临床疗效，监测患者细胞免疫功能、生活质量的变化，并评价其近期疗效和毒副反应。方法:选取2011年9月至2013年12月60例局部晚期食管癌患者，分为对照组30例，采用同步放化疗治疗；试验组30例，采用同步放化疗联合CIK细胞治疗。采用流式细胞术检测患者外周血T淋巴细胞亚群水平变化。结果:治疗后组间比较，试验组患者较对照组患者细胞免疫功能显著升高，其中CD3+T淋巴细胞百分率［(73.5±5.6）% vs （64.8±5.8）%，P=0.041］和CD3+CD56+T淋巴细胞百分率［(16.1±1.6）% vs （4.2±0.8）%,P=0.011］均较对照组显著升高。试验组的DCR较对照组明显提高，差异有统计学意义（90.0% vs 63.3%,P=0.030）。试验组生存质量明显改善且毒副反应轻。结论:与单纯同步放化疗相比，自体CIK细胞联合同步放化疗可显著提高局部晚期食管癌患者T淋巴细胞免疫功能，有效控制肿瘤生长，安全可靠。
|
| 关 键 词： | 食管癌 过继细胞免疫治疗 同步放化疗 生活质量 毒副反应 |
Autologous cytokine-induced killer cells combined with chemoradiation in the treatment of locally advanced esophageal carcinoma :A randomized control study |
| |
| Shu Xin,Li Guangxin,Zhu Xiling,Li Gong,Gan Quan,Wang Zhiyu.Autologous cytokine-induced killer cells combined with chemoradiation in the treatment of locally advanced esophageal carcinoma :A randomized control study[J].Journal of Modern Oncology,2015,0(10):1376-1380. |
| |
| Authors: | Shu Xin Li Guangxin Zhu Xiling Li Gong Gan Quan Wang Zhiyu |
| |
| Affiliation: | 1.Oncology Division,General Hospital of Armed Police Forces,Beijing 100039,China;2.Onocology Department,Beijing No.3 Hospital of Armed Police Forces,Beijing 100141,China;3.Nutritional Department,General Hospital of Armed Police Forces,Beijing 100039,China;4.Department of Biotherapy,Fourth Hospital of Hebei Medical University,Hebei Shijiazhuang 050011,China. |
| |
| Abstract: | Objective:To investigate the clinical efficacy and adverse events of autologous CIK cells combined chemoradiotherapy in patients with locally advanced esophageal cancer.Methods:Sixty untreated patients with locally advanced esophageal cancer were randomly divided into two groups.The 30 patients in the control group received chemoradiation.The 30 patients in the trial group were treated with chemoradiation in combination with autologous CIK cell transfusion were treated with chemoradiation in combination with autologous CIK cell transfusion.T lymphocyte subgroups were separated and measured by flow cytometry.Results:After treatment,the percentage of CD3+ T lymphocytes［(73.5±5.6）% vs （64.8±5.8）%，P=0.041］ and CD3+CD56+ T lymphocyte［(16.1±1.6）% vs （4.2±0.8）%,P=0.011］ was significantly higher in the trial group than that in the control group.The disease control rate(DCR) was markedly increased(90.0% vs 63.3%,P=0.030) in the trial group compared to the control group.The quality of life in the trial group improved significantly and had no significant extra toxicity.Conclusion:Compared with concurrent chemoradiotherapy alone,autologous CIK cells combined chemoradiotherapy can effectively enhance the immune activity of T lymphocyte,control the growth of tumor and improve the quality of life in patients with locally advanced esophageal cancer.Autologous CIK cells treatment is safe and can be tolerated. |
| |
| Keywords: | esophageal cancer adoptive immune cell therapy concurrent chemoradiation quality of life toxicity |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
|
